SCHEMBL24008989

SCHEMBL24008989

COc1cc2nccc(Cl)c2cc1Cl

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 4/20 0.58
CGAS Q8N884 1/20 0.52
PDGFRB P09619 2/20 0.46
PDGFRA P16234 2/20 0.46
EGFR P00533 3/20 0.44
RIPK2 O43353 2/20 0.44
NOD1 Q9Y239 1/20 0.44
DYRK1A Q13627 1/20 0.44
DOT1L Q8TEK3 1/20 0.43
GAK O14976 2/20 0.43
BMPR1B O00238 1/20 0.43
EPHB6 O15197 1/20 0.43
ABL1 P00519 1/20 0.43
LCK P06239 1/20 0.43
EPHA1 P21709 1/20 0.43
EPHA8 P29322 1/20 0.43
ACVR1 Q04771 1/20 0.43
MAP2K5 Q13163 1/20 0.43
COQ8A Q8NI60 1/20 0.43
NLK Q9UBE8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6004164 0.93 CGAS (0.59) SRCCGASPDGFRBPDGFRAEGFR
SCHEMBL29576504 0.91 SRC (0.60) SRCCGASPDGFRBPDGFRAEGFR
SCHEMBL29387468 0.91 SRC (0.60) SRCCGASPDGFRBPDGFRAEGFR
SCHEMBL359988 0.91 SRC (0.60) SRCCGASPDGFRBPDGFRAEGFR
Hydrochloric Acid SCHEMBL6432173 0.89 SRC (0.58) SRCCGASPDGFRBPDGFRAEGFR
SCHEMBL26178852 0.86 SRC (0.49) SRCCGASPDGFRBPDGFRAEGFR
SCHEMBL6004195 0.85 SRC (0.48) SRCCGASPDGFRBPDGFRAEGFR
SCHEMBL2064039 0.85 SRC (0.48) SRCCGASPDGFRBPDGFRAEGFR
SCHEMBL3838712 0.85 SRC (0.48) SRCCGASPDGFRBPDGFRAEGFR
SCHEMBL12682680 0.85 SRC (0.48) SRCCGASPDGFRBPDGFRAEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11780849-B2 Imino sulfanone inhibitors of ENPP1 VOLASTRA THERAPEUTICS, INC. (US) 2023-10-10 US disclosed
US-11780849-B2 Imino sulfanone inhibitors of ENPP1 VOLASTRA THERAPEUTICS, INC. (US) 2023-10-10 US disclosed
US-20230002406-A1 IMINO SULFANONE INHIBITORS OF ENPP1 VOLASTRA THERAPEUTICS, INC. (US) 2023-01-05 US disclosed
WO-2021225969-A1 IMINO SULFANONE INHIBITORS OF ENPP1 VOLASTRA THERAPEUTICS, INC. (US) 2021-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11780849-B2 Imino sulfanone inhibitors of ENPP1 ENPP1, ENPP3, SMPD1 SRC 1327/4885CGAS 261/4885PDGFRB 1742/4885
US-20230002406-A1 IMINO SULFANONE INHIBITORS OF ENPP1 ENPP1, ENPP3, SMPD1 SRC 1327/4885CGAS 261/4885PDGFRB 1742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.